Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1630]

Pathology of diffuse gastric cancer with CDH1 mutation

Prof. Fàtima Carneiro - University of Porto, Portugal

Pathology of diffuse gastric cancer with CDH1 mutation ( Prof. Fàtima Carneiro - University of Porto, Portugal )

Meet the Expert: Daniel Seymour

Daniel Seymour - BIO Ventures for Global Health, Seattle, USA

Meet the Expert: Daniel Seymour ( Daniel Seymour - BIO Ventures for Global Health, Seattle, USA )

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory...

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

$AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )$

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

$CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )$

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

Dr Katie Kelley - University of California San Francisco, San Francisco, USA

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )

Updated results from KEYNOTE-426 for metastatic kidney cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer ( Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA )

ASCO 2020: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2020: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

More from ecancer